Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST cells in severe osteogenesis imperfecta
NCT04623606Phase 2Unknown
- Sponsor
- Christian Medical College, Vellore
- Start
- May 2019
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic expanded fetal mesenchymal stem cells in osteogenesis imperfecta (OI), sponsored by Christian Medical College, Vellore. Primary endpoint: Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events at 16 months. Status: unknown.
02
Drugs
allogeneic expanded fetal mesenchymal stem cells
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT04623606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623606.